References
- Lepor H. Pathophysiology, epidemiology, and natural history of benign prostatic hyperplasia. Rev Urol 2004;6(Suppl 9):S3-S10
- Hoke GP, McWilliams GW. Epidemiology of benign prostatic hyperplasia and comorbidities in racial and ethnic minority populations. Am J Med 2008;121(8 Suppl 2):S3-S10
- Caine M. Alpha-adrenergic blockers for the treatment of benign prostatic hyperplasia. Urol Clin N Am 1990;17:641-9
- Peters DH, Sorkin EM. Finasteride. A review of its potential in the treatment of benign prostatic hyperplasia. Drugs 1993;46:177-208
- Chung JH, Lee JY, Kang DH, et al. Evaluation of patient outcome after discontinuation of alfuzosin treatment for benign prostatic hyperplasia: a multicentre, prospective study. Int J Clin Pract 2013;67:870-5
- Lyseng-Williamson KA, Jarvis B, Wagstaff AJ. Tamsulosin: an update of its role in the management of lower urinary tract symptoms. Drugs 2002;62:135-67
- Kim JJ, Han DH, Sung HH, et al. Efficacy and tolerability of tamsulosin 0.4 mg in Asian patients with lower urinary tract symptoms secondary to benign prostatic hyperplasia refractory to tamsulosin 0.2 mg: a randomized placebo controlled trial. Int J Urol 2014;21:677-82
- Wilt TJ, Mac Donald R, Rutks I. Tamsulosin for benign prostatic hyperplasia. Cochrane Database Syst Rev 2011;9:Cd002081
- Yoshida O, Takeuchi H, Hida S, et al. [Clinical efficacy and safety of long-term administration of YM617 for urinary obstruction of the lower urinary tract]. Hinyokika Kiyo 1991;37:421-9
- Kawabe K, Ueno A, Takimoto Y, et al. Use of an alpha 1-blocker, YM617, in the treatment of benign prostatic hypertrophy. YM617 Clinical Study Group. J Urol 1990;144:908-11;discussion 11-12
- Shim SR, Kim JH, Chang IH, et al. Is tamsulosin 0.2 mg effective and safe as a first-line treatment compared with other alpha blockers? A meta-analysis and a moderator focused study. Yonsei Med J 2016;57:407-18
- Grino PB, Bruskewitz R, Blaivas JG, et al. Maximum urinary flow rate by uroflowmetry: automatic or visual interpretation. J Urol 1993;149:339-41
- Abrams P, Schulman CC, Vaage S. Tamsulosin, a selective alpha 1c-adrenoceptor antagonist: a randomized, controlled trial in patients with benign prostatic ‘obstruction’ (symptomatic BPH). The European Tamsulosin Study Group. Br J Urol 1995;76:325-36
- Lepor H. Phase III multicenter placebo-controlled study of tamsulosin in benign prostatic hyperplasia. Tamsulosin Investigator Group. Urology 1998;51:892-900
- Osman NI, Chapple CR, Tammela TL, et al. Open-label, 9-month extension study investigating the uro-selective alpha-blocker silodosin in men with LUTS associated with BPH. World J Urol 2015;33:697-706
- Gacci M, Ficarra V, Sebastianelli A, et al. Impact of medical treatments for male lower urinary tract symptoms due to benign prostatic hyperplasia on ejaculatory function: a systematic review and meta-analysis. J Sex Med 2014;11:1554-66
- Song SH, Son H, Kim KT, et al. Effect of tamsulosin on ejaculatory function in BPH/LUTS. Asian J Androl 2011;13:846-50